FEATURED STORY

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

“Our platform of peptides captures the origins of Soricimed,” Robert Bruce, CEO, says in an interview with BioTuesdays. “We find ourselves on this path, especially in oncology but also in skin-care products and pesticides, because of the peptides we have discovered, rather than by trying to find a peptide to match a business opportunity.”

Soricimed’s lead oncology drug candidate, SOR-C13, is a synthetic peptide that is currently in an investigator-initiated Phase 1b dose escalation study with an efficacy/safety expansion arm that began in August 2019 at MD Anderson Cancer Center in Texas. SOR-C13 has received orphan drug status from the FDA for pancreatic and ovarian cancers.

Read the Story

SELECT BRIEFS

NYSE:FMS

Fresenius Medical Care

Gets FDA breakthrough device designation for hemodialysis system

NASDAQ:HEPA

Hepion Pharmaceuticals

To present CRV431’s potential in liver fibrosis at NASH summit

NASDAQ:PROF; TSX:PRN

Profound Medical

To begin trading on NASDAQ

TSX:ZENA

Zenabis Global

In cannabis cultivation accord with Tantalus Labs

More Briefs

Markets

About BioTuesdays

BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.

Want to be featured in BioTuesdays? Get in touch with us.

Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0

subscribe | unsubscribe | update your preferences